Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
- DOI
- 10.6084/m9.figshare.34936376.v1
- Published
- 2026
- Container
- Not recorded
- Publisher
- Taylor & Francis
- Open access
- yes
Credibility signals
limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.6084/m9.figshare.34936376.v1,
title = {Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial},
author = {Dongsheng Yue and Federico Cappuzzo and Wenxiang Wang and Hongxu Liu and Qixun Chen and Shengfei Wang and Shiang Jiin Leaw and Bin Yao and Frederick B. Barnes and Gisoo Barnes and Changli Wang},
year = {2026},
doi = {10.6084/m9.figshare.34936376.v1},
url = {https://doi.org/10.6084/m9.figshare.34936376.v1}
}RIS
TY - JOUR TI - Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial AU - Dongsheng Yue AU - Federico Cappuzzo AU - Wenxiang Wang AU - Hongxu Liu AU - Qixun Chen AU - Shengfei Wang AU - Shiang Jiin Leaw AU - Bin Yao AU - Frederick B. Barnes AU - Gisoo Barnes AU - Changli Wang PY - 2026 DO - 10.6084/m9.figshare.34936376.v1 UR - https://doi.org/10.6084/m9.figshare.34936376.v1 ER -
APA
Yue, D., Cappuzzo, F., Wang, W., Liu, H., Chen, Q., Wang, S., Leaw, S. J., Yao, B., Barnes, F. B., Barnes, G., & Wang, C. (2026). Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial. https://doi.org/10.6084/m9.figshare.34936376.v1
Source records
- datacite · retrieved 2026-11-09T05:44:04.627Z